Angela Lopez-Gitlitz
Overview
Explore the profile of Angela Lopez-Gitlitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
987
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Merseburger A, Agarwal N, Bjartell A, Uemura H, Soto A, Bhaumik A, et al.
BJU Int
. 2024 Jun;
134(6):982-991.
PMID: 38940282
Objective: To assess the association between achievement of prostate-specific antigen (PSA) levels ≤0.2 ng/mL (henceforth 'ultralow') and clinical outcomes in patients in the 'Targeted Investigational Treatment Analysis of Novel Anti-androgen'...
2.
Smith M, Sandhu S, George D, Chi K, Saad F, Thiery-Vuillemin A, et al.
J Manag Care Spec Pharm
. 2023 Jul;
29(7):758-768.
PMID: 37404070
Niraparib is a highly selective poly (adenosine diphosphateribose) polymerase-1 and poly (adenosine diphosphate-ribose) polymerase-2 inhibitor indicated for select patients with ovarian, fallopian tube, and primary peritoneal cancer. The phase 2...
3.
Chi K, Rathkopf D, Smith M, Efstathiou E, Attard G, Olmos D, et al.
J Clin Oncol
. 2023 Mar;
41(18):3339-3351.
PMID: 36952634
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including alterations, can sensitize cancer cells to poly (ADP-ribose) polymerase...
4.
Aggarwal R, Alumkal J, Szmulewitz R, Higano C, Bryce A, Lopez-Gitlitz A, et al.
Prostate Cancer
. 2022 Oct;
2022:5454727.
PMID: 36212187
Purpose: This randomized phase 2 study sought to assess the treatment effect of a finite duration of apalutamide with and without androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer...
5.
Tjollyn H, Ackaert O, Chien C, Lopez-Gitlitz A, McCarthy S, Perez Ruixo C, et al.
Cancer Chemother Pharmacol
. 2022 Apr;
89(5):629-641.
PMID: 35366072
Purpose: Apalutamide plus androgen-deprivation therapy (ADT) has been approved for treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) based on data from phase 3 TITAN study. This analysis was...
6.
Smith M, Scher H, Sandhu S, Efstathiou E, Lara Jr P, Yu E, et al.
Lancet Oncol
. 2022 Feb;
23(3):362-373.
PMID: 35131040
Background: Metastatic castration-resistant prostate cancers are enriched for DNA repair gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP proteins. We evaluated the anti-tumour activity...
7.
Saad F, Small E, Feng F, Graff J, Olmos D, Hadaschik B, et al.
Eur Urol
. 2021 Dec;
81(2):184-192.
PMID: 34916086
Background: Apalutamide plus androgen deprivation therapy (ADT) significantly improved metastasis-free survival (MFS), overall survival (OS), and time to prostate-specific antigen (PSA) progression in the placebo-controlled SPARTAN study of high-risk nonmetastatic...
8.
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes A, Chung B, et al.
J Urol
. 2021 Jul;
206(4):923.
PMID: 34296946
No abstract available.
9.
Smith M, Thomas S, Gormley M, Chowdhury S, Olmos D, Oudard S, et al.
Clin Cancer Res
. 2021 Jun;
27(16):4539-4548.
PMID: 34112710
Purpose: In the placebo-controlled SPARTAN study, apalutamide added to androgen-deprivation therapy (ADT) improved metastasis-free survival, second progression-free survival (PFS2), and overall survival (OS) in patients with nonmetastatic castration-resistant prostate cancer...
10.
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes A, Chung B, et al.
J Urol
. 2021 May;
206(4):914-923.
PMID: 34039013
Purpose: We performed an exploratory analysis of prostate cancer-related pain and fatigue on health-related quality of life in patients with metastatic castration-sensitive prostate cancer receiving apalutamide (240 mg/day) or placebo,...